A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

Inclusion Criteria: * Provided informed consent * Body mass index (BMI) \< 35 kg/m2 * Meets the diagnostic criteria for schizophrenia as defined in the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5), as established by a full psychiatric interview in conjunction with the Mini International Neuropsychiatric Interview (MINI) * Documented diagnosis of schizophrenia for at least 1 year before screening * Stable in terms of both positive and negative symptoms of schizophrenia over the last 3 months * Score of \> 20 on the PANSS original negative symptoms subscale (Sum of N1+N2+N3+N4+N5+N6+N7) at Screening and Baseline (Day -1) AND \< 4 points absolute difference between the 2 visits * Discontinued psychotropic medications without risk to their clinical status or safety by Baseline * Female subject, if not of childbearing potential, must be a woman who is post-menopausal or permanently sterilized * Female subject, if of childbearing potential, must test negative for pregnancy and must be using a double barrier contraceptive method * Must be normal metabolizer for P450 CYP 2D6, defined as a subject that has at least one functional allele (eg, \*1, \*2 or \*35), as determined by study-specific genotyping test before the first drug dose is administered * Has a caregiver or family member or health care personnel who can provide information towards assessment and support the subject in terms of compliance with the protocol Exclusion Criteria: * Current major depressive disorder, bipolar disorder, panic disorder, obsessive compulsive disorder, or intellectual disability (intellectual developmental disorder diagnosed by age 14) * PANSS item score of \> 4 on: * P4 Excitement/Hyperactivity * P6 Suspiciousness/persecution * P7 Hostility * G8 Uncooperativeness * G14 Poor impulse control * CDSS total score \> 6 * Score of ≥ 2 on any 2 of items 1, 2, or 3, or a score of ≥ 3 on item 4 of the Barnes Akathisia Rating Scale (BARS) * Has had electroconvulsive therapy (ECT), vagal nerve stimulation (VNS), or repetitive trans-cranial magnetic stimulation (r-TMS) within the 6 months prior to the Screening visit or who are scheduled for ECT, VNS, or r-TMS at any time during the study * Positive urine drug screen for drugs of abuse * Currently taking proton pump inhibitors (PPI) * Current systemic infection (eg, Hepatitis B, Hepatitis C, human immunodeficiency virus \[HIV\], tuberculosis) * Requires or may require concomitant treatment with any other medication likely to increase QT interval * Requires medication inhibiting CYP2D6 * Safety laboratory results show one or more of the following: potassium \<3.4 mmol/L, or calcium \<2.07 mmol/L, or magnesium \<0.70 mmol/L